Novel inhibitors of neutral and acid ceramidases and their application in experimental therapies of inflammatory and proliferative kidney diseases
Novel inhibitors of neutral and acid ceramidases and their application in experimental therapies of inflammatory and proliferative kidney diseases
批准号:
173771075
负责人:
Professor Dr. Christoph Arenz
金额:
$0.0万
依托单位国家:
德国
项目类别:
Priority Programmes
财政年份:
2010
资助国家:
德国
项目状态:
已结题
起止时间:
2009-12-31 至 2013-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The cellular equilibrium between ceramide and sphingosine-1-phosphate plays a key role in functional cellular responses like cell differentiation, cell growth and cell death as well as in some aspects of inflammatory events. This cellular “sphingolipid rheostat” is primarily regulated by three classes of enzymes: The ceramide generating sphingomyelinases, the ceramide degrading ceramidases and finally the sphingosine kinases. Our aim is to develop and synthesize novel inhibitors of the different ceramidases. We plan to test the substances in in vitro tests using recombinant human and murine enzymes. Afterwards, the cellular activity will be assessed with regards on cellular ceramidase activites, on cellular lipid concentrations and on cellular responses like cell-proliferation and apoptosis. Glomerulonephritis is a chronic inflammatory kidney disease in which hyperproliferation is an important aspect. We plan to test novel ceramidase inhibitors in cellular assays for inflammatory and hyperproliferative kidney diseases, but also in cancer cells. Finally promising candidates will be used for experimental therapies employing cellular and in vivo models of glomerulonephritis and cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Synthesis of small molecules for inhition of chlamydial growth
-
批准号:346427390
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:Professor Dr. Christoph Arenz
-
依托单位:
Chemical tools for the elucidation of the role of the acid sphingomyelinase under physiological or pathological conditions
-
批准号:266895703
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Professor Dr. Christoph Arenz
-
依托单位:
Nichtkodierende RNA-Moleküle und Chemische Biologie von Sphingolipiden
-
批准号:185148367
-
项目类别:Heisenberg Fellowships
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Professor Dr. Christoph Arenz
-
依托单位:
Synthese kleiner Moleküle zur Inhibition und Charakterisierung des intra- und extrazellulären Sphingomyelinasestoffwechsels
-
批准号:165890134
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Professor Dr. Christoph Arenz
-
依托单位:
Inhibition der mikroRNA-Reifung durch kleine Moleküle
-
批准号:33012208
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:2007
-
负责人:Professor Dr. Christoph Arenz
-
依托单位:
Synthese und biologische Charakterisierung von potentiellen Inhibitoren der sauren Sphingomyelinase
-
批准号:21459641
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:2005
-
负责人:Professor Dr. Christoph Arenz
-
依托单位:
Lipid Transport Proteins as Pharmacological Target Molecules
-
批准号:491223891
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Professor Dr. Christoph Arenz
-
依托单位:
Chemical tools for analysis and manipulation of ceramidases in human disease
-
批准号:457290043
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Professor Dr. Christoph Arenz
-
依托单位:
Small molecule experimental treatments of Niemann-Pick A/B disease in cell-based models
-
批准号:513549747
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Professor Dr. Christoph Arenz
-
依托单位:
国内基金
海外基金
登录
查看更多内容
内源性蛋白酶抑制剂SerpinA3N对缺血性脑卒中后血脑屏障的保护作用及其表达调控机制
-
批准号:82371317
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:万杰清
-
依托单位:
多羟基吡咯里西啶及其3-取代衍生物的合成及糖苷酶抑制活性的生物学评价
-
批准号:81060254
-
项目类别:地区科学基金项目
-
资助金额:28.0万元
-
批准年份:2010
-
负责人:李洪庆
-
依托单位:
2-取代的七元氮杂糖及其缩环产物六元氮杂糖的合成和糖苷酶抑制活性的生物学评价
-
批准号:30860341
-
项目类别:地区科学基金项目
-
资助金额:23.0万元
-
批准年份:2008
-
负责人:李洪庆
-
依托单位:
基于penicillide结构的类天然产物合成及其胆固醇酯转运蛋白抑制的研究
-
批准号:20872019
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2008
-
负责人:雷新胜
-
依托单位:
昆虫酚氧化酶抑制剂的抑制机理及其构效关系研究
-
批准号:30571237
-
项目类别:面上项目
-
资助金额:28.0万元
-
批准年份:2005
-
负责人:罗万春
-
依托单位:
建立甲状腺髓样癌的细胞和动物模型以及研究RET原癌基因突变的致病机制
-
批准号:30370666
-
项目类别:面上项目
-
资助金额:20.0万元
-
批准年份:2003
-
负责人:赵咏桔
-
依托单位: